Please enable JavaScript to continue using this application.

Compare $GLUE vs $JBIO | Chartloom

Compare

$GLUE vs $JBIO

Monte Rosa Therapeutics Inc · Jade Biosciences Inc

GLUE

Monte Rosa Therapeutics Inc

JBIO

Jade Biosciences Inc

Compare $GLUE vs $JBIO

Comparing Monte Rosa Therapeutics Inc and Jade Biosciences Inc

GLUEMonte Rosa Therapeutics Inc

JBIOJade Biosciences Inc

GLUEMonte Rosa Therapeutics Inc

Market cap

$870M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.85x

Rev growth (TTM)

-83.9%

YTD performance

-32.7%

52W performance

33.6%

FCF yield

-3.7%

JBIOJade Biosciences Inc

Market cap

$876M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

1.6%

52W performance

58.5%

FCF yield

-14.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GLUE

JBIO

Detailed metrics comparison

GLUE

Monte Rosa Therapeutics Inc

JBIO

Jade Biosciences Inc

Market Cap

GLUE$870M

JBIO$876M

Enterprise Value

GLUE$780M

JBIO$768M

Price

GLUE$10.30

JBIO$14.39

P/E Ratio

GLUEN/A

JBION/A

P/S Ratio

GLUE30.29x

JBIO0.00x

EV/Sales

GLUE27.15x

JBIO0.00x

EV/EBITDA

GLUE47.84x

JBIO0.00x

P/B Ratio

GLUE1.84x

JBIO2.04x

P/FCF Ratio

GLUEN/A

JBION/A

EV/FCF

GLUE-24.32x

JBIO-6.22x

PEG Ratio

GLUEN/A

JBION/A

Forward P/E (NTM)

GLUEN/A

JBION/A

Forward P/S (NTM)

GLUE21.85x

JBION/A

Revenue (TTM)

GLUE$29M

JBIO$0

Revenue Growth (YoY)

GLUE-83.9%

JBION/A

Forward Rev Growth

GLUE-58.1%

JBIO342.6%

Gross Margin (TTM)

GLUE0.0%

JBIO0.0%

Operating Margin (TTM)

GLUE0.0%

JBIO0.0%

EBITDA Margin (TTM)

GLUE-604.8%

JBIO0.0%

Net Margin (TTM)

GLUE-560.9%

JBIO0.0%

FCF Margin (TTM)

GLUE-111.7%

JBION/A

Net Income (TTM)

GLUE$-161M

JBIO$-125M

FCF (TTM)

GLUE$-32M

JBIO$-124M

EPS (TTM)

GLUE-$1.59

JBIO-$2.05

ROE (TTM)

GLUE-4331.0%

JBIO-4911.0%

ROA (TTM)

GLUE-2759.0%

JBIO-4561.0%

ROIC (TTM)

GLUE-4331.0%

JBIO-4911.0%

Cash

GLUE$90M

JBIO$107M

Debt

GLUE$0

JBIO$0

Net Cash/Debt

GLUE$90M

JBIO$107M

Current Ratio (TTM)

GLUE10.58x

JBIO14.93x

Quick Ratio (TTM)

GLUE10.49x

JBIO14.61x

Debt/Equity (TTM)

GLUE0.00x

JBIO0.00x

Debt/Assets (TTM)

GLUE0.0%

JBIO0.0%

Interest Coverage (TTM)

GLUEN/A

JBION/A

Net Debt/EBITDA (TTM)

GLUE0.00x

JBIO0.00x

Beta

GLUE1.34

JBIO1.78

52W Performance

GLUE33.6%

JBIO58.5%

YTD Performance

GLUE-32.7%

JBIO1.6%

% from 52W High

GLUE-60.0%

JBIO-48.6%

% from 52W Low

GLUE34.7%

JBIO72.1%

Asset Turnover (TTM)

GLUE0.05x

JBIO0.00x

FCF Yield (TTM)

GLUE-3.7%

JBIO-14.1%

Earnings Yield (TTM)

GLUE-18.5%

JBIO-14.3%

Dividend Yield (TTM)

GLUEN/A

JBION/A

Rule of 40

GLUE-195.5

JBIO0.0

EV/GP/RG

GLUEN/A

JBION/A

Ticker research

View GLUE research View JBIO research

Metric	GLUE Monte Rosa Therapeutics Inc	JBIO Jade Biosciences Inc
Market & Valuation
Market Cap	$870M	$876M
Enterprise Value	$780M	$768M
Price	$10.30	$14.39
P/E Ratio	N/A	N/A
P/S Ratio	30.29x	0.00x
EV/Sales	27.15x	0.00x
EV/EBITDA	47.84x	0.00x
P/B Ratio	1.84x	2.04x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.32x	-6.22x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.85x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$0
Revenue Growth (YoY)	-83.9%	N/A
Forward Rev Growth	-58.1%	342.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-604.8%	0.0%
Net Margin (TTM)	-560.9%	0.0%
FCF Margin (TTM)	-111.7%	N/A
Net Income (TTM)	$-161M	$-125M
FCF (TTM)	$-32M	$-124M
EPS (TTM)	-$1.59	-$2.05
ROE (TTM)	-4331.0%	-4911.0%
ROA (TTM)	-2759.0%	-4561.0%
ROIC (TTM)	-4331.0%	-4911.0%
Financial Health
Cash	$90M	$107M
Debt	$0	$0
Net Cash/Debt	$90M	$107M
Current Ratio (TTM)	10.58x	14.93x
Quick Ratio (TTM)	10.49x	14.61x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	1.78
52W Performance	33.6%	58.5%
YTD Performance	-32.7%	1.6%
% from 52W High	-60.0%	-48.6%
% from 52W Low	34.7%	72.1%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-3.7%	-14.1%
Earnings Yield (TTM)	-18.5%	-14.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-195.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GLUE research	View JBIO research

Valuation

P/S Ratio

JBIO

0.00x

GLUE

30.29x

EV/FCF

GLUE

-24.32x

JBIO

-6.22x

Growth & revenue

Revenue Growth TTM

GLUE

-83.9%

Forward Revenue Growth

JBIO

342.6%

GLUE

-58.1%

Profitability & performance

Gross Margin

GLUE

0.0%

JBIO

0.0%

ROE

GLUE

-4331.0%

JBIO

-4911.0%

FCF Yield %

GLUE

-3.7%

JBIO

-14.1%

52-Week Performance

JBIO

58.5%

GLUE

33.6%

Detailed metrics comparison

GLUE

Monte Rosa Therapeutics Inc

JBIO

Jade Biosciences Inc

Market Cap

GLUE$870M

JBIO$876M

Enterprise Value

GLUE$780M

JBIO$768M

Price

GLUE$10.30

JBIO$14.39

P/E Ratio

GLUEN/A

JBION/A

P/S Ratio

GLUE30.29x

JBIO0.00x

EV/Sales

GLUE27.15x

JBIO0.00x

EV/EBITDA

GLUE47.84x

JBIO0.00x

P/B Ratio

GLUE1.84x

JBIO2.04x

P/FCF Ratio

GLUEN/A

JBION/A

EV/FCF

GLUE-24.32x

JBIO-6.22x

PEG Ratio

GLUEN/A

JBION/A

Forward P/E (NTM)

GLUEN/A

JBION/A

Forward P/S (NTM)

GLUE21.85x

JBION/A

Revenue (TTM)

GLUE$29M

JBIO$0

Revenue Growth (YoY)

GLUE-83.9%

JBION/A

Forward Rev Growth

GLUE-58.1%

JBIO342.6%

Gross Margin (TTM)

GLUE0.0%

JBIO0.0%

Operating Margin (TTM)

GLUE0.0%

JBIO0.0%

EBITDA Margin (TTM)

GLUE-604.8%

JBIO0.0%

Net Margin (TTM)

GLUE-560.9%

JBIO0.0%

FCF Margin (TTM)

GLUE-111.7%

JBION/A

Net Income (TTM)

GLUE$-161M

JBIO$-125M

FCF (TTM)

GLUE$-32M

JBIO$-124M

EPS (TTM)

GLUE-$1.59

JBIO-$2.05

ROE (TTM)

GLUE-4331.0%

JBIO-4911.0%

ROA (TTM)

GLUE-2759.0%

JBIO-4561.0%

ROIC (TTM)

GLUE-4331.0%

JBIO-4911.0%

Cash

GLUE$90M

JBIO$107M

Debt

GLUE$0

JBIO$0

Net Cash/Debt

GLUE$90M

JBIO$107M

Current Ratio (TTM)

GLUE10.58x

JBIO14.93x

Quick Ratio (TTM)

GLUE10.49x

JBIO14.61x

Debt/Equity (TTM)

GLUE0.00x

JBIO0.00x

Debt/Assets (TTM)

GLUE0.0%

JBIO0.0%

Interest Coverage (TTM)

GLUEN/A

JBION/A

Net Debt/EBITDA (TTM)

GLUE0.00x

JBIO0.00x

Beta

GLUE1.34

JBIO1.78

52W Performance

GLUE33.6%

JBIO58.5%

YTD Performance

GLUE-32.7%

JBIO1.6%

% from 52W High

GLUE-60.0%

JBIO-48.6%

% from 52W Low

GLUE34.7%

JBIO72.1%

Asset Turnover (TTM)

GLUE0.05x

JBIO0.00x

FCF Yield (TTM)

GLUE-3.7%

JBIO-14.1%

Earnings Yield (TTM)

GLUE-18.5%

JBIO-14.3%

Dividend Yield (TTM)

GLUEN/A

JBION/A

Rule of 40

GLUE-195.5

JBIO0.0

EV/GP/RG

GLUEN/A

JBION/A

Ticker research

View GLUE research View JBIO research

Metric	GLUE Monte Rosa Therapeutics Inc	JBIO Jade Biosciences Inc
Market & Valuation
Market Cap	$870M	$876M
Enterprise Value	$780M	$768M
Price	$10.30	$14.39
P/E Ratio	N/A	N/A
P/S Ratio	30.29x	0.00x
EV/Sales	27.15x	0.00x
EV/EBITDA	47.84x	0.00x
P/B Ratio	1.84x	2.04x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.32x	-6.22x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.85x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$0
Revenue Growth (YoY)	-83.9%	N/A
Forward Rev Growth	-58.1%	342.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-604.8%	0.0%
Net Margin (TTM)	-560.9%	0.0%
FCF Margin (TTM)	-111.7%	N/A
Net Income (TTM)	$-161M	$-125M
FCF (TTM)	$-32M	$-124M
EPS (TTM)	-$1.59	-$2.05
ROE (TTM)	-4331.0%	-4911.0%
ROA (TTM)	-2759.0%	-4561.0%
ROIC (TTM)	-4331.0%	-4911.0%
Financial Health
Cash	$90M	$107M
Debt	$0	$0
Net Cash/Debt	$90M	$107M
Current Ratio (TTM)	10.58x	14.93x
Quick Ratio (TTM)	10.49x	14.61x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	1.78
52W Performance	33.6%	58.5%
YTD Performance	-32.7%	1.6%
% from 52W High	-60.0%	-48.6%
% from 52W Low	34.7%	72.1%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-3.7%	-14.1%
Earnings Yield (TTM)	-18.5%	-14.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-195.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GLUE research	View JBIO research